Articles

Back to Articles

The Potential of Canagliflozin for the Treatment of Type 2 Diabetes

(Pub. 15th November 2012)

Canagliflozin, is a unique inhibitor of sodium glucose co-transporter 2, and looks to be a promising novel treatment for adults with type 2 diabetes in the near future. On June 9, 2012 J&J’s Janssen Research & Development unit announced the results from five Phase lll clinical trials, which were presented at the 72nd American Diabetes Association Annual Scientific Sessions. Two of these studies compared Canagliflozin to the current standard treatments of sitagliptin and glimepiride. Results in favor of Canagliflozin were positive, showing that a once daily 300 mg dose of this medication provided significantly greater reductions in A1C levels relative to both comparators. In addition, when compared to the standard treatments of sitagliptin and glimepiride the incidence of adverse effects was similar. 

The global Phase 3 Canagliflozin trial enrolled over 10,300 patients in nine studies. This is the largest late-stage clinical trial and development program for an investigational product to treat type 2 diabetes submitted to health authorities worldwide, as of late 2012.  Both the efficacy and safety profile of Canagliflozin was diligently studied across a wide spectrum of type 2 diabetes management. The vast array of treatment management included adult patients with type 2 diabetes who were treated only with diet and exercise, to adult patients with type 2 diabetes who needed regular insulin injections to maintain their glycemic control. There were also three large studies which encompassed patients in special populations, which were older adult patients with type 2 diabetes, adult patients with type 2 diabetes who currently had moderate renal impairment, and patients with type 2 diabetes who had or were considered to be at high risk for cardiovascular disease. These widespread and inclusive studies have created a genuine excitement and hope for Canagliflozin among not only the pharmaceutical industry, but also those physicians and patients dealing with type 2 diabetes on a daily basis.

Canagliflozin is the most advanced anti-diabetes project in the pipeline at J&J and has showed positive trends in lowering blood sugar in patients with long duration insulin therapy. If approved, the drug would be J&J's first diabetes medicine.

National Diabetes Month is upon us, November 2012. Education, information, research and development are all extremely needed to combat the future predicted onslaught in cases of type 2 diabetes worldwide. One example of the far-reaching effects that this devastating disease has had worldwide is the BBC news report regarding the drastic uptick in cases of type 2 diabetes in Northern Ireland. On October 29, 2012 the BBC UK reported that the number of people in Northern Ireland living with type 1 and type 2 diabetes has increased by 33% during the last five years, according to the latest figures. Additionally a rise in cases of diabetes overall was documented as 25% in England, 20% in Wales and 18% in Scotland. Diabetes UK revealed that a majority of these new cases are attributable to type 2 diabetes cases. The National Director of Diabetes UK Northern Ireland, Iain Foster, described these statistics as "very worrying". Indeed, this has become a worldwide crisis regarding type 2 diabetes, and it is clear that new treatments as well as preventative care are needed for the future health of all people.

YES Pharma is proud to be a leading supply source for Canagliflozin (CAS#: 842133-18-0) to several global pharmaceutical companies and academic research institutes, while recognizing that we play a significant part in the battle against type II Diabetes. The Canagliflozin that YES Pharma supplies is intended for laboratory R&D use only.

References:

http://www.abstractsonline.com/plan/start.aspx?mkey={0F70410F-8DF3-49F5-A63D-3165359F5371}
Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Improves Glycemia and is Well Tolerated in Type 2 Diabetes Mellitus Subjects with Moderate Renal Impairment” June 10
Diabetes, Obesity and Metabolism, Volume 13, Issue 7, pages 669–672, July 2011

 

  • Products currently covered by valid US patents are offered only for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
  • Any patent infringement and resulting liability is solely at buyer risk.
  • Products covered by valid patents are not offered or supplied for commercial use.

 

 

 

 

Dun and Bradstreet